The Oncology Institute, Inc.
TOI
$2.96
-$0.14-4.52%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 27.79% | 21.67% | 17.53% | 17.64% | 21.33% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 27.79% | 21.67% | 17.53% | 17.64% | 21.33% |
| Cost of Revenue | 25.60% | 20.77% | 17.96% | 20.54% | 28.24% |
| Gross Profit | 41.55% | 27.10% | 15.18% | 3.19% | -9.36% |
| SG&A Expenses | -2.09% | -7.90% | -7.90% | -7.70% | -5.30% |
| Depreciation & Amortization | 10.45% | 14.00% | 9.34% | 8.03% | 7.05% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.80% | 13.47% | 10.97% | 12.44% | 17.98% |
| Operating Income | 39.98% | 35.36% | 26.27% | 16.22% | 0.08% |
| Income Before Tax | 6.07% | 5.87% | 7.95% | 11.88% | 22.19% |
| Income Tax Expenses | -- | 58.28% | 26.82% | -- | -- |
| Earnings from Continuing Operations | 6.27% | 5.63% | 7.90% | 11.79% | 22.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.27% | 5.63% | 7.90% | 11.79% | 22.16% |
| EBIT | 39.98% | 35.36% | 26.27% | 16.22% | 0.08% |
| EBITDA | 45.87% | 40.65% | 30.18% | 18.86% | 0.85% |
| EPS Basic | 20.34% | 16.71% | 14.45% | 13.82% | 23.34% |
| Normalized Basic EPS | 26.49% | 22.63% | 19.84% | 18.84% | 5.23% |
| EPS Diluted | 21.05% | 17.11% | 13.73% | 13.41% | 22.90% |
| Normalized Diluted EPS | 26.49% | 22.63% | 19.84% | 18.84% | 5.23% |
| Average Basic Shares Outstanding | 23.01% | 15.25% | 8.64% | 2.62% | 1.92% |
| Average Diluted Shares Outstanding | 23.01% | 15.25% | 8.64% | 2.62% | 1.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |